ADCT vs MYD Comparison

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes. The fund invests a majority of its assets in municipal bonds exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). These bonds are predominantly long-term (with a maturity of more than ten years at the time of investment), and rated as investment grade, or deemed to be of comparable quality by the investment adviser at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.